Geode Capital Management’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-467,870
| Closed | -$1.89M | – | 4461 |
|
|
2025
Q1 | $1.89M | Buy |
467,870
+22,759
| +5% | +$75.9K | ﹤0.01% | 3057 |
|
|
2024
Q4 | $1.43M | Buy |
445,111
+17,460
| +4% | +$59.2K | ﹤0.01% | 3244 |
|
|
2024
Q3 | $958K | Buy |
427,651
+124,787
| +41% | +$288K | ﹤0.01% | 3367 |
|
|
2024
Q2 | $651K | Buy |
302,864
+104,363
| +53% | +$186K | ﹤0.01% | 3471 |
|
|
2024
Q1 | $407K | Buy |
198,501
+24,657
| +14% | +$49.2K | ﹤0.01% | 3687 |
|
|
2023
Q4 | $398K | Buy |
173,844
+895
| +0.5% | +$1.95K | ﹤0.01% | 3698 |
|
|
2023
Q3 | $294K | Buy |
172,949
+44,362
| +34% | +$101K | ﹤0.01% | 3817 |
|
|
2023
Q2 | $318K | Buy |
128,587
+56,997
| +80% | +$156K | ﹤0.01% | 3830 |
|
|
2023
Q1 | $161K | Hold |
71,590
| – | – | ﹤0.01% | 4148 |
|
|
2022
Q4 | $365K | Buy |
71,590
+2,048
| +3% | +$14.8K | ﹤0.01% | 3820 |
|
|
2022
Q3 | $723K | Buy |
69,542
+2,664
| +4% | +$31.7K | ﹤0.01% | 3549 |
|
|
2022
Q2 | $688K | Buy |
66,878
+2,201
| +3% | +$28.8K | ﹤0.01% | 3584 |
|
|
2022
Q1 | $1.14M | Buy |
64,677
+8,681
| +16% | +$186K | ﹤0.01% | 3547 |
|
|
2021
Q4 | $1.74M | Hold |
55,996
| – | – | ﹤0.01% | 3436 |
|
|
2021
Q3 | $1.85M | Buy |
55,996
+7,055
| +14% | +$209K | ﹤0.01% | 3386 |
|
|
2021
Q2 | $1.44M | Sell |
48,941
-30,914
| -39% | -$857K | ﹤0.01% | 3420 |
|
|
2021
Q1 | $2.51M | Buy |
79,855
+15,978
| +25% | +$535K | ﹤0.01% | 3145 |
|
|
2020
Q4 | $1.69M | Buy |
63,877
+5,765
| +10% | +$146K | ﹤0.01% | 3166 |
|
|
2020
Q3 | $1.56M | Buy |
58,112
+10,280
| +21% | +$247K | ﹤0.01% | 3010 |
|
|
2020
Q2 | $947K | Buy |
47,832
+11,866
| +33% | +$216K | ﹤0.01% | 3154 |
|
|
2020
Q1 | $543K | Buy |
35,966
+6,846
| +24% | +$121K | ﹤0.01% | 3251 |
|
|
2019
Q4 | $500K | Sell |
29,120
-734
| -2% | -$12.3K | ﹤0.01% | 3499 |
|
|
2019
Q3 | $743K | Buy |
29,854
+139
| +0.5% | +$3.81K | ﹤0.01% | 3344 |
|
|
2019
Q2 | $900K | Buy |
29,715
+24,019
| +422% | +$943K | ﹤0.01% | 3266 |
|
|
2019
Q1 | $162K | Hold |
5,696
| – | – | ﹤0.01% | 3786 |
|
|
2018
Q4 | $103K | Buy |
5,696
+139
| +3% | +$3.31K | ﹤0.01% | 3849 |
|
|
2018
Q3 | $198K | Buy |
+5,557
| New | +$194K | ﹤0.01% | 3769 |
|
Geode Capital Management's CKPT Position: Q2 2025 in Review
Geode Capital Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 467,870 shares — an estimated $1.89M sold.
Geode Capital Management first reported a position in CKPT in Q3 2018 and held it in 27 quarters. The position peaked at $2.51M in Q1 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Geode Capital Management reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Geode Capital Management sold 467,870 Checkpoint Therapeutics shares in Q2 2025, an estimated $1.89M.
- Geode Capital Management first reported a position in Checkpoint Therapeutics in Q3 2018 and held it in 27 quarters.
- Geode Capital Management's Checkpoint Therapeutics position peaked at $2.51M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.